Stayble Therapeutics' board proposes voluntary liquidation and delisting
The shareholders in the research company Stayble Therapeutics are called to an extraordinary general meeting, which also serves as the first control meeting, on Thursday, May 7 in Gothenburg.
ANNONS
The company has, as previously announced, prepared a control balance sheet, which has been reviewed by the company’s auditor. The control balance sheet shows that equity is less than half of the registered share capital.
The board has considered possible financing alternatives but assessed that there are no conditions to ensure continued operations. The board therefore proposes that the meeting resolve on voluntary liquidation of the company and that the company’s assets be sold to the highest bidder.
The board proposes that attorney Patric Lundin, Wåhlin Advokater, be appointed liquidator. The board’s preliminary assessment is that distribution can be expected to take place within seven to twelve months after the Companies Registration Office’s decision to appoint a liquidator. The liquidation proceeds are conservatively estimated at zero kronor per share.
Provided that the meeting has first resolved on voluntary liquidation, the board proposes that the meeting resolve on delisting of the company’s shares from Nasdaq First North Growth Market.
